China channel feed

Star­tups raised mil­lions to in-li­cense drugs to Chi­na. Then the mod­el fell apart

Last year
Deals
In Focus

Law­mak­ers call for 'line in the sand' be­tween US and Chi­nese biotech com­pa­nies

Last year
Pharma
Law

Sen­ate com­mit­tee ad­vances bill tar­get­ing Chi­nese man­u­fac­tur­ers as BIO faces at­tack for back­ing WuXi

Last year
Pharma
Manufacturing

Join­ing con­gres­sion­al skep­ti­cism of Chi­na's role in biotech, Biden ex­ec­u­tive or­der tar­gets da­ta pri­va­cy is­sues

Last year
Law

Chi­nese API man­u­fac­tur­er re­ceives FDA warn­ing let­ter af­ter QC em­ploy­ee says test re­sults 'in my mind'

Last year
FDA+
Manufacturing

Law­mak­ers’ ex­plo­sive charges turn a glob­al spot­light on Chi­na’s WuXi, and it’s feel­ing the heat

Last year
Bioregnum

In clash over sci­ence and na­tion­al se­cu­ri­ty, Chi­nese ri­val to Il­lu­mi­na strug­gles with US ex­pan­sion

Last year
In Focus
Diagnostics

Lian­Bio to shut­ter, end­ing Shang­hai-based start­up’s transat­lantic am­bi­tions

Last year
People
Startups

Seat­tle biotech found­ed by for­mer Seagen lead­ers nabs $112M for three clin­i­cal-stage AD­Cs

Last year
Financing
Startups

Up­dat­ed: ‘Ruth­less’ pipeline pri­or­i­ti­za­tion, obe­si­ty and Chi­na: Three take­aways from As­traZeneca’s Q4 

Last year
Pharma

House com­mit­tee plans hear­ing on Chi­nese biotech com­pe­ti­tion as ten­sions mount

Last year
Pharma

I-Mab Bio­phar­ma to split US, Chi­na busi­ness­es to cut costs, mit­i­gate po­ten­tial risks

Last year
Deals

Ar­riVent out­lines plans for $135M IPO in sec­ond biotech list­ing of 2024

Last year
Financing
Startups

As­traZeneca reshuf­fles Chi­na lead­er­ship, sets up bio­phar­ma group to mir­ror glob­al struc­ture

Last year
People
Pharma

BioN­Tech pays $20M up­front for two mon­o­clon­al an­ti­bod­ies from Chi­na's WuXi Bi­o­log­ics

Last year
Deals

CNS biotech My­robal­an Ther­a­peu­tics rais­es $24M Se­ries A to en­ter the clin­ic

Last year
Financing
Startups

RTW, Bay­er back Cy­to­ki­net­ics-al­lied Ji Xing Phar­ma­ceu­ti­cals with $162M: #JPM24

Last year
Financing
Pharma

GSK to buy asth­ma biotech Aio­los Bio for up to $1.4B three months af­ter start­up emerged: #JPM24

Last year
Deals
Pharma

Bei­jing on­col­o­gy biotech Avi­s­tone rais­es $140M Se­ries B for com­mer­cial­iza­tion in Chi­na, ex­pan­sion in­to US

Last year
Financing

An­oth­er day, an­oth­er ADC: On­Cusp se­cures $100M Se­ries A from No­vo, Or­biMed and oth­ers to run PhI tri­al

Last year
Financing
Startups

Ex­clu­sive: Af­ter Turn­ing Point suc­cess, on­col­o­gy vets in-li­cense first as­set for Aven­zo Ther­a­peu­tics

Last year
Startups
Deals

Trail­ing No­var­tis and Eli Lil­ly, ra­dio­phar­ma­ceu­ti­cals start­up Full-Life Tech­nolo­gies nabs $63M to test new PS­MA drug

Last year
Financing
Manufacturing

Roche inks $50M ADC pact with Chi­nese biotech as field­'s flur­ry spills over in­to 2024

Last year
Deals
Pharma

As­traZeneca makes $1B deal for Gra­cell and its cell ther­a­pies, adding to Chi­na ties

Last year
Deals
Cell/Gene Tx
First page Previous page 567891011 Next page Last page
A service from the Financial Times